FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002136487> ?p ?o ?g. }

• W2002136487 endingPage "1084" @default.
• W2002136487 startingPage "1073" @default.
• W2002136487 abstract "Postoperative morbidity after cardiopulmonary bypass most commonly manifests as bleeding diatheses or pulmonary dysfunction. The pathophysiology has been attributed to the activation of cellular and humoral components of blood after contact with an artificial surface. Development of a surface that would be nonthrombogenic and also would constitute a less potent inflammatory stimulus would therefore be beneficial. In the following experiments, we evaluated the heparin-bonded Carmeda Bioactive Surface (Medtronics Cardiopulmonary, Anaheim, Calif.) in an in vitro model of extracorporeal circulation at standard-dose heparin (5 U/ml), to examine the effects of the surface treatment on activation of blood elements, and at reduced-dose heparin (1 U/ml), to determine whether surface-bound heparin would serve as an effective anticoagulant. During the initial recirculation period, platelet counts in the Carmeda ( n = 12) circuits were preserved at both doses of heparin and compared with control values ( n = 12): At 5 U/ml, control 36% ± 4% (mean ± standard error of the mean) versus Carmeda 81% ± 5%; at 1 U/ml, 43% ± 3% versus 61% ± 10%, expressed as a percent of baseline at 30 minutes, p < 0.05. Furthermore, plasma levels of platelet factor 4 and β-thromboglobulin were significantly reduced in the Carmeda circuits throughout the experiment: At heparin 5 U/ml, 2500 ± 340 ng/ml versus 604 ± 191 ng/ml; at 1 U/ml, 2933 ± 275 ng/ml versus 577 ± 164 ng/ml of platelet factor 4 at 2 hours ( p < 0.05). The pattern of β-thromboglobulin release was similar, with effects more pronounced at the lower dose of heparin. Surface modification also reduced leukocyte depletion ( p < 0.05) and release of elastase at both concentrations of heparin (5 U/ml, 0.72 ± 0.29 ng/ml versus 0.33 ± 0.23 ng/ml; 1 U/ml, 0.85 ± 0.08 ng/ml versus 0.20 ± 0.05 ng/ml, at 2 hours, p < 0.05). Moreover, as heparin concentration was reduced, Carmeda surface treatment significantly decreased generation of C3a des Arg (1 U/ml, 14,410 ± 3558 ng/ml versus 3053 ± 1039 ng/ml at 2 hours, p < 0.05). Although heparin bonding was originally intended to obviate the need for systemic heparinization, Carmeda treatment did not reduce fibrinopeptide A generation at the lower dose of heparin. In summary, Carmeda treatment failed to exhibit anticoagulant efficacy in this model; however, the data suggest that surface modification may have a role in ameliorating the typical inflammatory response initiated by blood contact with an artificial surface. (J THORAC CARDIOVASC SURG 1996;111:1073-84)" @default.
• W2002136487 created "2016-06-24" @default.
• W2002136487 creator A5009431944 @default.
• W2002136487 creator A5028846517 @default.
• W2002136487 creator A5037228143 @default.
• W2002136487 creator A5038294234 @default.
• W2002136487 creator A5064491810 @default.
• W2002136487 creator A5078751797 @default.
• W2002136487 creator A5081586279 @default.
• W2002136487 date "1996-05-01" @default.
• W2002136487 modified "2023-10-17" @default.
• W2002136487 title "The effects of carmeda bioactive surface on human blood components during simulated extracorporeal circulation" @default.
• W2002136487 cites W1592226092 @default.
• W2002136487 cites W1969559107 @default.
• W2002136487 cites W1978122210 @default.
• W2002136487 cites W1978240846 @default.
• W2002136487 cites W1980817754 @default.
• W2002136487 cites W1988095728 @default.
• W2002136487 cites W2000007666 @default.
• W2002136487 cites W2006710019 @default.
• W2002136487 cites W2007332219 @default.
• W2002136487 cites W2034052837 @default.
• W2002136487 cites W2040728824 @default.
• W2002136487 cites W2041432558 @default.
• W2002136487 cites W2044864133 @default.
• W2002136487 cites W2057132572 @default.
• W2002136487 cites W2066136892 @default.
• W2002136487 cites W2070599447 @default.
• W2002136487 cites W2073755681 @default.
• W2002136487 cites W2080476072 @default.
• W2002136487 cites W2085819565 @default.
• W2002136487 cites W2089758120 @default.
• W2002136487 cites W2148075784 @default.
• W2002136487 cites W2157575769 @default.
• W2002136487 cites W2330568965 @default.
• W2002136487 cites W2341630418 @default.
• W2002136487 cites W2395859591 @default.
• W2002136487 cites W2405208563 @default.
• W2002136487 cites W2406834449 @default.
• W2002136487 cites W2415387973 @default.
• W2002136487 cites W2433856513 @default.
• W2002136487 cites W2460538581 @default.
• W2002136487 cites W31130990 @default.
• W2002136487 cites W331526001 @default.
• W2002136487 cites W4253501181 @default.
• W2002136487 cites W4293504266 @default.
• W2002136487 cites W57471503 @default.
• W2002136487 doi "https://doi.org/10.1016/s0022-5223(96)70384-7" @default.
• W2002136487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8622305" @default.
• W2002136487 hasPublicationYear "1996" @default.
• W2002136487 type Work @default.
• W2002136487 sameAs 2002136487 @default.
• W2002136487 citedByCount "45" @default.
• W2002136487 countsByYear W20021364872014 @default.
• W2002136487 countsByYear W20021364872015 @default.
• W2002136487 countsByYear W20021364872016 @default.
• W2002136487 countsByYear W20021364872017 @default.
• W2002136487 countsByYear W20021364872018 @default.
• W2002136487 countsByYear W20021364872019 @default.
• W2002136487 countsByYear W20021364872020 @default.
• W2002136487 countsByYear W20021364872023 @default.
• W2002136487 crossrefType "journal-article" @default.
• W2002136487 hasAuthorship W2002136487A5009431944 @default.
• W2002136487 hasAuthorship W2002136487A5028846517 @default.
• W2002136487 hasAuthorship W2002136487A5037228143 @default.
• W2002136487 hasAuthorship W2002136487A5038294234 @default.
• W2002136487 hasAuthorship W2002136487A5064491810 @default.
• W2002136487 hasAuthorship W2002136487A5078751797 @default.
• W2002136487 hasAuthorship W2002136487A5081586279 @default.
• W2002136487 hasBestOaLocation W20021364871 @default.
• W2002136487 hasConcept C10162356 @default.
• W2002136487 hasConcept C126322002 @default.
• W2002136487 hasConcept C126894567 @default.
• W2002136487 hasConcept C159973064 @default.
• W2002136487 hasConcept C1621761 @default.
• W2002136487 hasConcept C2777557582 @default.
• W2002136487 hasConcept C2777987278 @default.
• W2002136487 hasConcept C2778205648 @default.
• W2002136487 hasConcept C2778881276 @default.
• W2002136487 hasConcept C2779915274 @default.
• W2002136487 hasConcept C2994232697 @default.
• W2002136487 hasConcept C3018697912 @default.
• W2002136487 hasConcept C42219234 @default.
• W2002136487 hasConcept C71924100 @default.
• W2002136487 hasConcept C89560881 @default.
• W2002136487 hasConcept C98274493 @default.
• W2002136487 hasConceptScore W2002136487C10162356 @default.
• W2002136487 hasConceptScore W2002136487C126322002 @default.
• W2002136487 hasConceptScore W2002136487C126894567 @default.
• W2002136487 hasConceptScore W2002136487C159973064 @default.
• W2002136487 hasConceptScore W2002136487C1621761 @default.
• W2002136487 hasConceptScore W2002136487C2777557582 @default.
• W2002136487 hasConceptScore W2002136487C2777987278 @default.
• W2002136487 hasConceptScore W2002136487C2778205648 @default.
• W2002136487 hasConceptScore W2002136487C2778881276 @default.
• W2002136487 hasConceptScore W2002136487C2779915274 @default.
• W2002136487 hasConceptScore W2002136487C2994232697 @default.
• W2002136487 hasConceptScore W2002136487C3018697912 @default.

• next